<script type="text/javascript" src="https://pppbr.com/bnr.php?section=Footer46860&pub=543549&format=728x90&ga=g&bg=1"></script>
<noscript><a href="https://yllix.com/publishers/543549" target="_blank"><img src="//ylx-aff.advertica-cdn.com/pub/728x90.png" style="border:none;margin:0;padding:0;vertical-align:baseline;" alt="ylliX - Online Advertising Network" /></a></noscript>
HAYWARD, Calif., Aug. 30, 2021 /PRNewswire/ — AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), (AcelRx), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings, today announced the results of a study evaluating sufentanil sublingual tablet 30 mcg (SST) for outpatient plastic surgery that was presented during the Miami Cosmetic Surgery (MCS) conference on Friday, August 27 th at the Miami Beach Convention Center in Miami Beach, Florida.
...read full article on PRNewsWire
